Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Temporal comparison of biologic medication prices between the United States and Australia
By
- AMS
posted
Jun 01, 2020 01:20 PM
0
Recommend
.
0 comments
1 view
Permalink
Related Content
Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review
- AMS
Added Sep 25, 2020
Blog Entry
Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration
- AMS
Added Jan 06, 2020
Blog Entry
Language proficiency and biologics access: a population study of psoriasis patients in the United States
- AMS
Added Sep 15, 2020
Blog Entry
Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review
- AMS
Added May 25, 2020
Blog Entry
Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines
The Aesthetic GUIDE
Added Mar 04, 2024
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic